|
Hot Stocks
| ShowHide Related Items >><< - 09:44 Today
- Alpha Teknova Inc trading halted, volatility trading pause
- 06:34 Today Stephens
- Alpha Teknova price target lowered to $15 from $22 at Stephens
- 10/14/21 Cowen
- Alpha Teknova price target raised to $30 from $24 at Cowen
- 08/10/22
- Alpha Teknova reports Q2 EPS (22c) vs. (52c) in last year's quarter
- 03/15/22
- Alpha Teknova sees FY22 revenue $44M-$48M, consensus $42.04M
- 03/15/22
- Alpha Teknova reports Q4 EPS (13c), consensus (17c)
- 02/28/22
- Alpha Teknova sees Q4 revenue $10-$10.1M, consensus $8.45M
|
|
Recommendations
| ShowHide Related Items >><< - 09:47 Today
- Haemonetics shares rose 9% on Wednesday following Q1 results
- 07/11/22
- Axogen appoints William Burke to board of directors
- 06/24/22
- Haemonetics completes move to manufacturing facility in Clinton, PA
- 05/10/22
- Haemonetics rises 16.0%
- 09:05 Today Barrington
- Haemonetics price target raised to $88 from $77 at Barrington
- 07/01/22 Morgan Stanley
- Haemonetics price target raised to $70 from $60 at Morgan Stanley
- 05/11/22 Barrington
- Haemonetics price target raised to $77 from $71 at Barrington
- 02/09/22 Barrington
- Haemonetics price target raised to $71 from $67 at Barrington
- 05/10/22
- Haemonetics sees 2023 adjusted EPS $2.50-$2.90, consensus $2.75
- 05/10/22
- Haemonetics reports Q4 adjusted EPS 65c, consensus 60c
|
|
Hot Stocks
|
GSK plc is down -7.9%, or… ShowHide Related Items >><< - 08/08/22
- Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056
- 08/08/22
- GSK, IQVIA launch Vaccine Track platform
- 07/29/22
- ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir
- 07/28/22
- ViiV Healthcare announces data from unblinded phase of HPTN 084 study
- 08:34 Today Deutsche Bank
- Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank
- 08/09/22 Baird
- Mersana Therapeutics price target raised to $20 from $18 at Baird
- 08/08/22 UBS
- GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
- 08/05/22 Morgan Stanley
- GSK plc resumed with an Equal Weight at Morgan Stanley
- 07/27/22
- GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year
- 04/27/22
- GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER
- 04/27/22
- GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year
- 04/13/22
- GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B
- 07:56 Today
- GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports
- 07/18/22
- GSK CEO says split will help deal with 'perennial underperformance,' FT reports
- 06/27/22
- GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says
- 06/27/22
- GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says
- 08/09/22
- What You Missed On Wall Street On Tuesday
- 08/09/22
- What You Missed On Wall Street This Morning
- 08/05/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/18/22
- What You Missed On Wall Street This Morning
- 08/10/22
- GSK plc (ADR) call volume above normal and directionally bullish
- 07/29/22
- GSK plc (ADR) call volume above normal and directionally bullish
- 07/22/22
- Two new option listings and one option delisting on July 22nd
- 07/20/22
- One new option listing and two option delistings on July 20th
|
|
Hot Stocks
|
Six Flags is down -18.1%,… ShowHide Related Items >><< - $21.11 /
-4.695 (-18.19%) - 08:04 Today
- Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22%
- 06:08 Today
- Six Flags drops 8% to $23.70 after Q2 results miss estimates
- 07/26/22
- Novanta to replace Six Flags in the S&P 400 at open on 7/26
- 07/26/22
- Six Flags to replace Natus Medical in the S&P 600 at open on 7/26
- $21.11 /
-4.695 (-18.19%) - 07/08/22 Citi
- Six Flags downgraded to Neutral from Buy at Citi
- 06/24/22 Stifel
- Six Flags price target lowered to $35 from $52 at Stifel
- 06/21/22 B. Riley
- Six Flags downgraded to Neutral from Buy at B. Riley
- 05/13/22 Truist
- Six Flags price target lowered to $32 from $46 at Truist
- $21.11 /
-4.695 (-18.19%) - 06:00 Today
- Six Flags reports Q2 EPS 53c, consensus $1.02
- 08/10/22
- Notable companies reporting before tomorrow's open
- 08/10/22
- Notable companies reporting before tomorrow's open
- 05/12/22
- Six Flags reports Q1 EPS (76c), consensus ($1.04)
- $21.11 /
-4.695 (-18.19%) - 08:51 Today
- Fly Intel: Pre-market Movers
- 07/21/22
- Fly Intel: After-Hours Movers
- 07/08/22
- What You Missed On Wall Street On Friday
- 07/08/22
- What You Missed On Wall Street This Morning
|
|
Hot Stocks
| ShowHide Related Items >><< - 09:42 Today
- Invitae trading resumes
- 09:37 Today
- Invitae trading halted, volatility trading pause
- 08/10/22
- Invitae rises 46.1%
- 08/08/22
- Cathie Wood's ARK Investment bought 813K shares of Invitae today
- 08/10/22 JPMorgan
- Invitae cut to Underweight at JPMorgan with future growth yet to be proven
- 08/10/22 JPMorgan
- Invitae downgraded to Underweight from Neutral at JPMorgan
- 07/26/22 Cowen
- Invitae cut to Market Perform at Cowen on debt refinancing uncertainty
- 07/26/22 Cowen
- Invitae downgraded to Market Perform from Outperform at Cowen
- 08/09/22
- Invitae backs FY22 revenue growth of low double digits, consensus $542.96M
- 08/09/22
- Invitae reports Q2 adjusted EPS (68c), consensus (76c)
- 07/18/22
- Invitae sees second half of FY22 revenue flat over first half of FY22
- 07/18/22
- Invitae sees Q2 revenue $136M, consensus $142.74M
- 08/10/22
- What You Missed On Wall Street On Wednesday
- 08/10/22
- What You Missed On Wall Street This Morning
- 07/21/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 07/18/22
- Fly Intel: After-Hours Movers
- 08:00 Today
- Invitae call buyer realizes 3500% same-day gains
- 05/03/22
- Invitae options imply 14.1% move in share price post-earnings
- 02/24/22
- Invitae options imply 14.1% move in share price post-earnings
|
|
Hot Stocks
| ShowHide Related Items >><< - 07/11/22
- Axogen appoints William Burke to board of directors
- 06/24/22
- Haemonetics completes move to manufacturing facility in Clinton, PA
- 05/10/22
- Haemonetics rises 16.0%
- 03/21/22
- Haemonetics names James D'Arecca CFO
- 09:05 Today Barrington
- Haemonetics price target raised to $88 from $77 at Barrington
- 07/01/22 Morgan Stanley
- Haemonetics price target raised to $70 from $60 at Morgan Stanley
- 05/11/22 Barrington
- Haemonetics price target raised to $77 from $71 at Barrington
- 02/09/22 Barrington
- Haemonetics price target raised to $71 from $67 at Barrington
- 05/10/22
- Haemonetics sees 2023 adjusted EPS $2.50-$2.90, consensus $2.75
- 05/10/22
- Haemonetics reports Q4 adjusted EPS 65c, consensus 60c
|
|
Hot Stocks
|
Solo Brands is up 14.7%,… ShowHide Related Items >><< - 08/09/22
- Solo Brands rises 14.2%
- 05/27/22
- Solo Brands rises 19.5%
- 05/27/22
- Solo Brands rises 13.2%
- 05/12/22
- Solo Brands falls -15.0%
- 08/02/22 Citi
- Solo Brands transferred with Buy rating at Citi
- 05/13/22 Citi
- Solo Brands price target lowered to $11 from $16 at Citi
- 03/30/22 Citi
- Solo Brands price target lowered to $16 from $20 at Citi
- 01/11/22 Citi
- Solo Brands upgraded to Buy from Neutral at Citi
- 06:55 Today
- Solo Brands sees FY22 revenue growth in mid-20% range, consensus $548.76M
- 06:54 Today
- Solo Brands reports Q2 adjusted EPS 40c, consensus 28c
- 05/12/22
- Solo Brands sees FY22 revenue $540M-$570M, consensus $556.7M
- 05/12/22
- Solo Brands reports Q1 adjusted EPS 19c, consensus 8c
|
|
Hot Stocks
| ShowHide Related Items >><< - 06/15/22
- Dutch Bros CEO: Demand is not where we would like it to be
- 05/12/22
- Dutch Bros falls -28.4%
- 05/12/22
- Dutch Bros falls -40.1%
- 05/12/22
- Dutch Bros falls -35.8%
- 06:31 Today Baird
- Dutch Bros price target raised to $46 from $30 at Baird
- 06:14 Today Piper Sandler
- Dutch Bros price target raised to $50 from $44 at Piper Sandler
- 07/11/22 Baird
- Dutch Bros downgraded to Neutral from Outperform at Baird
- 06/09/22 Barclays
- Dutch Bros price target raised to $34 from $25 at Barclays
- 08/10/22
- Dutch Bros backs FY22 revenue view at least $715M, consensus $713.11M
- 08/10/22
- Dutch Bros reports Q2 adjusted EPS 5c, consensus 7c
- 05/11/22
- Dutch Bros sees FY22 revenue $700M-$715M, consensus $717.22M
- 05/11/22
- Dutch Bros reports Q1 adjusted EPS (2c), consensus 1c
|
|
Hot Stocks
| ShowHide Related Items >><< - 07/26/22
- Vizio up 3% after Protocol report on Comcast acquisition talks
- 06/23/22
- Vizio Smart TVs now integrated with Tik Tok TV
- 05/12/22
- Vizio sees Q2 adjusted EBITDA $3M-$7M
- 04/26/22
- Nielsen expands Smart TV data deal with Vizio
- 08/08/22 BofA
- Vizio price target lowered to $15 from $17 at BofA
- 07/22/22 JPMorgan
- Vizio price target lowered to $14 from $20 at JPMorgan
- 07/12/22 Guggenheim
- Vizio price target lowered to $12 from $14 at Guggenheim
- 05/13/22 Piper Sandler
- Vizio price target lowered to $15 from $21 at Piper Sandler
- 08/10/22
- Vizio sees Q3 adjusted EBITDA $8M-$13M
- 08/10/22
- Vizio reports Q2 EPS 1c vs (8c) last year
- 05/12/22
- Vizio reports Q1 EPS (6c), consensus (5c)
- 03/03/22
- Vizio sees Q1 adjusted EBITDA ($2M)-$2M
- 07/26/22
- Comcast approached Vizio about potential acquisition, Protocol says
- 08/10/22
- Fly Intel: After-Hours Movers
- 05/12/22
- Fly Intel: After-Hours Movers
|
|
Downgrade
| ShowHide Related Items >><< - 07/15/22
- Coupang rises 7.9%
- 07/01/22
- Coupang rises 13.4%
- 07/01/22
- Coupang rises 9.1%
- 05/12/22
- Coupang rises 24.8%
- 06:39 Today Mizuho
- Coupang price target raised to $22 from $18 at Mizuho
- 08/10/22 Macquarie
- Macquarie started Coupang at Outperform with $26 target yesterday
- 08/09/22 Macquarie
- Coupang initiated with an Outperform at Macquarie
- 06/30/22 Credit Suisse
- Coupang upgraded to Outperform at Credit Suisse following underperformance
- 08/10/22
- Coupang raises FY22 adjusted EBITDA view
- 08/10/22
- Coupang reports Q2 EPS (4c), consensus (11c)
- 05/11/22
- Coupang reports Q1 EPS (12c), consensus (17c)
- 03/02/22
- Coupang sees 2022 adjusted EBITDA loss less than ($400M)
|
